This is all really interesting, you have done an outstanding job of due diligence on GALT's technology.
Personally, I believe that GALT has already shown (in Cohort 3 of the Phase 1) enough of an indication of efficacy as it relates to NASH (the alpha2 macroglobulin changes after short treatment) that they will eventually get approval from the FDA for this drug (assuming they can get it through all 3 phases) because there is a very low barrier for efficacy (no viable treatment other than transplant). This is a drug with no SAEs (to date) and even if treatment extended the time for a transplant by several years (by slowing down or partially reversing fibrosis) it would be approved.
None of this means much, though, until they produce Phase 2 results AND the markets respond. I don't understand why the share price is $1.50, it makes no sense to me, but markets work in strange ways.
Regarding financing for the company, though, I don't think Czirr is actively involved at this point in time and the 10X Fund is unlikely to add more money in the future, if not they would not have engaged the hedge funds for the last round.
News 
Market Data 
Discover 
